A Phase 3 interventional study of linagliptin2.5mg/metformin1000mg and linagliptin2.5mg/metformin1000mg in Diabetes Mellitus, Type 2, sponsored by Boehringer Ingelheim. Completed at 56 sites in 4 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2015-04-24.
Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 67 studies testing linagliptin in Diabetes Mellitus, Type 2 — 1 open to participants now, 1 under way, none of them phase 3. Linagliptin · Diabetes Mellitus, Type 2.
Among the 67 studies testing linagliptin in Diabetes Mellitus, Type 2, this one is the 7th largest by enrollment, is one of 6 that started in 2012, is one of 31 in phase 3, and was the 31st registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →1 of the 67 studies testing linagliptin in Diabetes Mellitus, Type 2 is open now, in 1 country. Recruiting first, the newest first:
Bahria University · Sites in Pakistan
Ages 30–55
By country, each count listing its studies:
Linagliptin: first FDA approval 2011 (TRADJENTA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
67 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 6 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 876 is above the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 175 across the 67 interventional studies. Of the 60 that completed or were terminated, 41 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
42 of 67 have an industry lead sponsor. The 10 most frequent:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
130 studies in Diabetes Mellitus, Type 2 by Boehringer Ingelheim: 2 open now, 3 under way, 2 of them phase 3. Of 125 finished, 109 (87%) have results posted.
Among the 130 studies in Diabetes Mellitus, Type 2 by Boehringer Ingelheim, this one is the 19th largest by enrollment of the 96 interventional ones that give a count, is one of 9 that started in 2012, is one of 50 in phase 3, and was the 65th registered.
Boehringer Ingelheim’s Diabetes Mellitus, Type 2 studies by the year they started, since 1997.
None of the studies under way reaches primary completion within a year.
Among the 67 studies testing linagliptin in Diabetes Mellitus, Type 2, from their registry updates:
Among Boehringer Ingelheim’s 130 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
Reduced factorial design study with 24 week randomized treatment of initial combination therapy with linagliptin and metformin in T2DM patients
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
patient to receive a tablet containing linagliptin 2.5mg and metformin 500mg BID
Drug: linagliptin 5mg · Drug: Metformin 500mg
patient to receive a tablet containing linagliptin 2.5mg and metformin 1000mg BID
Drug: linagliptin 5mg · Drug: Metformin 1000mg
patient to receive a tablet containing metformin 500mg BID
Drug: linagliptin2.5mg/metformin500mg
patient to receive a tablet containing metformin 1000mg BID
Drug: linagliptin2.5mg/metformin1000mg
patient to receive a tablet containing linagliptin 5mg once daily
Drug: linagliptin2.5mg/metformin1000mg · Drug: linagliptin2.5mg/metformin500mg
linagliptin2.5mg/metformin1000mg BID
linagliptin2.5mg/metformin1000mg BID
linagliptin 5mg once daily
Metformin 500mg BID
linagliptin2.5mg/metformin500mg BID
linagliptin2.5mg/metformin500mg BID
linagliptin 5mg once daily
Metformin 1000mg BID
The Change From Baseline in HbA1c After 24 Weeks of Treatment in Main Group
The change from baseline in HbA1c after 24 weeks of treatment in main group. The mean was adjusted by baseline HbA1c and treatment group.
Time frame: Baseline and week 24
The Change From Baseline in HbA1c After 24 Weeks of Treatment in Main Group - FAS (OC)
The change from baseline in HbA1c after 24 weeks of treatment in main group. Only subjects from the FAS with measured HbA1c values (observed cases \[OC\]) were considered. The mean was adjusted by treatment, baseline HbA1c, week and treatment\*week. The sensitivity analysis was added as the primary analysis failed with borderline results.
Time frame: Baseline and week 24
The Change From Baseline in HbA1c After 12 Weeks of Treatment in APG
The change from baseline in HbA1c after 12 weeks of treatment in additional parallel group (APG) The mean was adjusted by baseline HbA1c and treatment group.
Time frame: Baseline and week 12
The Occurrence of Treat to Target Efficacy Response in Terms of HbA1c < 7.0 % After 24 Weeks of Treatment in Main Group
The occurrence of treat to target efficacy response in terms of HbA1c \< 7.0 % after 24 weeks of treatment in main group.
Time frame: Week 24 (after first drug administration)
The Occurrence of Treat to Target Efficacy Response in Terms of HbA1c < 7.0 % After 12 Weeks of Treatment in APG
The occurrence of treat to target efficacy response in terms of HbA1c \< 7.0 % after 12 weeks of treatment in APG.
Time frame: Week 12 (after first drug administration)
The Occurrence of Treat to Target Efficacy Response in Terms of HbA1c < 6.5% After 24 Weeks of Treatment in Main Group
The occurrence of treat to target efficacy response in terms of HbA1c \< 6.5% after 24 weeks of treatment in main group.
Time frame: Week 24 (after first drug administration)
The Occurrence of Treat to Target Efficacy Response in Terms of HbA1c < 6.5% After 12 Weeks of Treatment in APG
The occurrence of treat to target efficacy response in terms of HbA1c \< 6.5% after 12 weeks of treatment in APG.
Time frame: Week 12 (after first drug administration)
The Occurrence of Relative Efficacy Response in Main Group
The occurrence of relative efficacy response (HbA1c lowering by at least 0.5% after 24 weeks of treatment) in main group
Time frame: From baseline until week 24
The Occurrence of Relative Efficacy Response in APG
The Occurrence of Relative Efficacy Response (HbA1c Lowering by at Least 0.5% After 12 Weeks of Treatment) in APG
Time frame: From baseline until week 12
The Change in Fasting Plasma Glucose (FPG) From Baseline After 24 Weeks of Treatment in Main Group
The change in fasting plasma glucose (FPG) from baseline after 24 weeks of treatment in main group. Adjusted mean: The model includes continuous baseline HbA1c, continuous baseline FPG and treatment group.
Time frame: Baseline and week 24
The Change in Fasting Plasma Glucose (FPG) From Baseline After 12 Weeks of Treatment in APG
The Change in Fasting Plasma Glucose (FPG) From Baseline After 12 Weeks of Treatment in APG. Adjusted mean: The model includes continuous baseline HbA1c, continuous baseline FPG and treatment group.
Time frame: Baseline and week 12
The Frequency of Patients With Use of Rescue Therapy During 24 Week Treatment Period in Main Group
The frequency of patients with use of rescue therapy during 24 week treatment period in main group. For this analysis the main group contrast 'Metformin 1000mg BID, Linagliptin 2.5mg / Metformin 1000mg BID' could not be analysed due to lack of events in the Metformin 1000mg BID group.
Time frame: From baseline until week 24
The Frequency of Patients With Use of Rescue Therapy During 12 Week Treatment Period in APG
The Frequency of Patients With Use of Rescue Therapy During 12 Week Treatment Period in APG.
Time frame: From baseline until week 12
| Milestone | Main: Linagliptin 5mg QD | Main: Metformin 500mg BID | Main: Metformin 1000mg BID | Main: Linagliptin 2.5mg / Metformin 500mg BID | Main: Linagliptin 2.5mg / Metformin 1000mg BID | APG: Linagliptin 5mg QD | APG: Linagliptin 2.5mg / Metformin 1000mg BID |
|---|---|---|---|---|---|---|---|
| Started | 147 | 145 | 144 | 147 | 147 | 71 | 72 |
| Completed | 130 | 137 | 127 | 137 | 131 | 64 | 65 |
| Not completed | 17 | 8 | 17 | 10 | 16 | 7 | 7 |
| Withdrew: Adverse event | 3 | 4 | 9 | 2 | 7 | 3 | 5 |
| Withdrew: Lack of efficacy | 3 | 1 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Non compliance with protocol | 0 | 2 | 1 | 3 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 2 | 1 | 2 | 2 | 0 | 0 | 1 |
| Withdrew: Refused to continue trial medication | 8 | 0 | 4 | 2 | 8 | 1 | 1 |
| Withdrew: Other reason | 1 | 0 | 1 | 1 | 1 | 2 | 0 |
The change from baseline in HbA1c after 24 weeks of treatment in main group. The mean was adjusted by baseline HbA1c and treatment group.
| percentage | Main: Linagliptin 5mg QD | Main: Metformin 500mg BID | Main: Metformin 1000mg BID | Main: Linagliptin 2.5mg / Metformin 500mg BID | Main: Linagliptin 2.5mg / Metformin 1000mg BID |
|---|---|---|---|---|---|
| The Change From Baseline in HbA1c After 24 Weeks of Treatment in Main Group | -1.29 ± 0.08 | -1.64 ± 0.08 | -2.07 ± 0.08 | -2.15 ± 0.08 | -2.29 ± 0.08 |
The occurrence of treat to target efficacy response in terms of HbA1c \< 7.0 % after 24 weeks of treatment in main group.
| percentage of participants | Main: Linagliptin 5mg QD | Main: Metformin 500mg BID | Main: Metformin 1000mg BID | Main: Linagliptin 2.5mg / Metformin 500mg BID | Main: Linagliptin 2.5mg / Metformin 1000mg BID |
|---|---|---|---|---|---|
| The Occurrence of Treat to Target Efficacy Response in Terms of HbA1c < 7.0 % After 24 Weeks of Treatment in Main Group | 43.6 (35.2 to 52.2) | 50.0 (41.6 to 58.4) | 69.0 (60.3 to 76.8) | 72.1 (63.9 to 79.4) | 77.1 (69.3 to 83.8) |
The occurrence of treat to target efficacy response in terms of HbA1c \< 7.0 % after 12 weeks of treatment in APG.
| percentage of participants | APG: Linagliptin 5mg QD | APG: Linagliptin 2.5mg / Metformin 1000mg BID |
|---|---|---|
| The Occurrence of Treat to Target Efficacy Response in Terms of HbA1c < 7.0 % After 12 Weeks of Treatment in APG | 27.1 (17.2 to 39.1) | 58.8 (46.2 to 70.6) |
The occurrence of treat to target efficacy response in terms of HbA1c \< 6.5% after 24 weeks of treatment in main group.
| percentage of participants | Main: Linagliptin 5mg QD | Main: Metformin 500mg BID | Main: Metformin 1000mg BID | Main: Linagliptin 2.5mg / Metformin 500mg BID | Main: Linagliptin 2.5mg / Metformin 1000mg BID |
|---|---|---|---|---|---|
| The Occurrence of Treat to Target Efficacy Response in Terms of HbA1c < 6.5% After 24 Weeks of Treatment in Main Group | 23.4 (16.7 to 31.3) | 34.7 (27.0 to 43.1) | 50.4 (41.6 to 59.2) | 56.3 (47.8 to 64.6) | 60.3 (51.7 to 68.4) |
The occurrence of treat to target efficacy response in terms of HbA1c \< 6.5% after 12 weeks of treatment in APG.
| percentage of participants | APG: Linagliptin 5mg QD | APG: Linagliptin 2.5mg / Metformin 1000mg BID |
|---|---|---|
| The Occurrence of Treat to Target Efficacy Response in Terms of HbA1c < 6.5% After 12 Weeks of Treatment in APG | 15.7 (8.1 to 26.4) | 36.8 (25.4 to 49.3) |
The change from baseline in HbA1c after 24 weeks of treatment in main group. Only subjects from the FAS with measured HbA1c values (observed cases \[OC\]) were considered. The mean was adjusted by treatment, baseline HbA1c, week and treatment\*week. The sensitivity analysis was added as the primary analysis failed with borderline results.
| percentage | Main: Linagliptin 5mg QD | Main: Metformin 500mg BID | Main: Metformin 1000mg BID | Main: Linagliptin 2.5mg / Metformin 500mg BID | Main: Linagliptin 2.5mg / Metformin 1000mg BID |
|---|---|---|---|---|---|
| The Change From Baseline in HbA1c After 24 Weeks of Treatment in Main Group - FAS (OC) | -1.34 ± 0.08 | -1.68 ± 0.08 | -2.08 ± 0.08 | -2.16 ± 0.08 | -2.38 ± 0.08 |
The change from baseline in HbA1c after 12 weeks of treatment in additional parallel group (APG) The mean was adjusted by baseline HbA1c and treatment group.
| percentage | APG: Linagliptin 5mg QD | APG: Linagliptin 2.5mg / Metformin 1000mg BID |
|---|---|---|
| The Change From Baseline in HbA1c After 12 Weeks of Treatment in APG | -3.46 ± 0.22 | -4.71 ± 0.22 |
The occurrence of relative efficacy response (HbA1c lowering by at least 0.5% after 24 weeks of treatment) in main group
| percentage of participants | Main: Linagliptin 5mg QD | Main: Metformin 500mg BID | Main: Metformin 1000mg BID | Main: Linagliptin 2.5mg / Metformin 500mg BID | Main: Linagliptin 2.5mg / Metformin 1000mg BID |
|---|---|---|---|---|---|
| The Occurrence of Relative Efficacy Response in Main Group | 73.0 (64.9 to 80.2) | 80.6 (73.1 to 86.7) | 89.5 (83.0 to 94.1) | 93.0 (87.4 to 96.6) | 89.4 (83.1 to 93.9) |
The Occurrence of Relative Efficacy Response (HbA1c Lowering by at Least 0.5% After 12 Weeks of Treatment) in APG
| percentage of participants | APG: Linagliptin 5mg QD | APG: Linagliptin 2.5mg / Metformin 1000mg BID |
|---|---|---|
| The Occurrence of Relative Efficacy Response in APG | 84.3 (73.6 to 91.9) | 91.2 (81.8 to 96.7) |
The change in fasting plasma glucose (FPG) from baseline after 24 weeks of treatment in main group. Adjusted mean: The model includes continuous baseline HbA1c, continuous baseline FPG and treatment group.
| mg/dL | Main: Linagliptin 5mg QD | Main: Metformin 500mg BID | Main: Metformin 1000mg BID | Main: Linagliptin 2.5mg / Metformin 500mg BID | Main: Linagliptin 2.5mg / Metformin 1000mg BID |
|---|---|---|---|---|---|
| The Change in Fasting Plasma Glucose (FPG) From Baseline After 24 Weeks of Treatment in Main Group | -15.03 ± 2.25 | -29.87 ± 2.23 | -42.07 ± 2.31 | -39.33 ± 2.24 | -47.44 ± 2.26 |
The Change in Fasting Plasma Glucose (FPG) From Baseline After 12 Weeks of Treatment in APG. Adjusted mean: The model includes continuous baseline HbA1c, continuous baseline FPG and treatment group.
| mg/dL | APG: Linagliptin 5mg QD | APG: Linagliptin 2.5mg / Metformin 1000mg BID |
|---|---|---|
| The Change in Fasting Plasma Glucose (FPG) From Baseline After 12 Weeks of Treatment in APG | -56.70 ± 6.53 | -91.92 ± 6.48 |
The frequency of patients with use of rescue therapy during 24 week treatment period in main group. For this analysis the main group contrast 'Metformin 1000mg BID, Linagliptin 2.5mg / Metformin 1000mg BID' could not be analysed due to lack of events in the Metformin 1000mg BID group.
| percentage of participants | Main: Linagliptin 5mg QD | Main: Metformin 500mg BID | Main: Metformin 1000mg BID | Main: Linagliptin 2.5mg / Metformin 500mg BID | Main: Linagliptin 2.5mg / Metformin 1000mg BID |
|---|---|---|---|---|---|
| The Frequency of Patients With Use of Rescue Therapy During 24 Week Treatment Period in Main Group | 7.1 (3.5 to 12.7) | 2.1 (0.4 to 6.0) | 0.0 (0.0 to 2.7) | 1.4 (0.2 to 5.0) | 2.1 (0.4 to 6.1) |
The Frequency of Patients With Use of Rescue Therapy During 12 Week Treatment Period in APG.
| percentage of participants | APG: Linagliptin 5mg QD | APG: Linagliptin 2.5mg / Metformin 1000mg BID |
|---|---|---|
| The Frequency of Patients With Use of Rescue Therapy During 12 Week Treatment Period in APG | 10.0 (4.1 to 19.5) | 1.5 (0.0 to 7.9) |
Collected over From first drug administration (week 1) until end of treatment, up to 24 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Main: Linagliptin 5mg QD | — | 2/147 (1.4%) | 30/147 (20.4%) |
| Main: Metformin 500mg BID | — | 1/145 (0.7%) | 31/145 (21.4%) |
| Main: Metformin 1000mg BID | — | 2/144 (1.4%) | 42/144 (29.2%) |
| Main: Linagliptin 2.5mg / Metformin 500mg BID | — | 1/147 (0.7%) | 32/147 (21.8%) |
| Main: Linagliptin 2.5mg / Metformin 1000mg BID | — | 4/147 (2.7%) | 41/147 (27.9%) |
| APG: Linagliptin 5mg QD up to Week 12 | — | 1/71 (1.4%) | 20/71 (28.2%) |
| APG: Linagliptin 2.5mg / Metformin 1000mg BID up to Week 12 | — | 1/72 (1.4%) | 15/72 (20.8%) |
| APG: Linagliptin 5mg After Week 12 | — | 0/33 (0%) | 2/33 (6.1%) |
| APG: Linagliptin 5mg - Linagliptin 2.5mg / Met After Week 12 | — | 1/31 (3.2%) | 9/31 (29%) |
| APG: Linagliptin 2.5mg / Metformin 1000mg After Week 12 | — | 1/65 (1.5%) | 9/65 (13.8%) |
| Event | Main: Linagliptin 5mg QD | Main: Metformin 500mg BID | Main: Metformin 1000mg BID | Main: Linagliptin 2.5mg / Metformin 500mg BID | Main: Linagliptin 2.5mg / Metformin 1000mg BID | APG: Linagliptin 5mg QD up to Week 12 | APG: Linagliptin 2.5mg / Metformin 1000mg BID up to Week 12 | APG: Linagliptin 5mg After Week 12 | APG: Linagliptin 5mg - Linagliptin 2.5mg / Met After Week 12 | APG: Linagliptin 2.5mg / Metformin 1000mg After Week 12 |
|---|---|---|---|---|---|---|---|---|---|---|
| GastritisGastrointestinal disorders | 0/147 | 0/145 | 0/144 | 0/147 | 0/147 | 0/71 | 0/72 | 0/33 | 1/31 | 0/65 |
| PharyngotonsillitisInfections and infestations | 0/147 | 0/145 | 0/144 | 0/147 | 0/147 | 0/71 | 0/72 | 0/33 | 0/31 | 1/65 |
| Septic shockInfections and infestations | 0/147 | 0/145 | 0/144 | 0/147 | 0/147 | 0/71 | 0/72 | 0/33 | 0/31 | 1/65 |
| Urinary tract infectionInfections and infestations | 0/147 | 0/145 | 0/144 | 0/147 | 0/147 | 0/71 | 0/72 | 0/33 | 0/31 | 1/65 |
| DehydrationMetabolism and nutrition disorders | 0/147 | 0/145 | 0/144 | 0/147 | 0/147 | 0/71 | 0/72 | 0/33 | 0/31 | 1/65 |
| Renal failure acuteRenal and urinary disorders | 0/147 | 0/145 | 0/144 | 0/147 | 0/147 | 0/71 | 0/72 | 0/33 | 0/31 | 1/65 |
| Cerebral infarctionNervous system disorders | 0/147 | 0/145 | 0/144 | 0/147 | 0/147 | 1/71 | 0/72 | 0/33 | 0/31 | 0/65 |
| PneumoniaInfections and infestations | 0/147 | 0/145 | 0/144 | 0/147 | 0/147 | 0/71 | 1/72 | 0/33 | 0/31 | 0/65 |
| Acute coronary syndromeCardiac disorders | 0/147 | 0/145 | 1/144 | 0/147 | 0/147 | 0/71 | 0/72 | 0/33 | 0/31 | 0/65 |
| OtosclerosisEar and labyrinth disorders | 0/147 | 0/145 | 1/144 | 0/147 | 0/147 | 0/71 | 0/72 | 0/33 | 0/31 | 0/65 |
| Event | Main: Linagliptin 5mg QD | Main: Metformin 500mg BID | Main: Metformin 1000mg BID | Main: Linagliptin 2.5mg / Metformin 500mg BID | Main: Linagliptin 2.5mg / Metformin 1000mg BID | APG: Linagliptin 5mg QD up to Week 12 | APG: Linagliptin 2.5mg / Metformin 1000mg BID up to Week 12 | APG: Linagliptin 5mg After Week 12 | APG: Linagliptin 5mg - Linagliptin 2.5mg / Met After Week 12 | APG: Linagliptin 2.5mg / Metformin 1000mg After Week 12 |
|---|---|---|---|---|---|---|---|---|---|---|
| HyperuricaemiaMetabolism and nutrition disorders | 11/147 | 13/145 | 13/144 | 8/147 | 11/147 | 4/71 | 4/72 | 1/33 | 6/31 | 4/65 |
| HyperglycaemiaMetabolism and nutrition disorders | 7/147 | 4/145 | 0/144 | 4/147 | 2/147 | 12/71 | 2/72 | 0/33 | 2/31 | 2/65 |
| DiarrhoeaGastrointestinal disorders | 5/147 | 8/145 | 16/144 | 7/147 | 14/147 | 2/71 | 4/72 | 1/33 | 1/31 | 1/65 |
| Upper respiratory tract infectionInfections and infestations | 6/147 | 6/145 | 14/144 | 12/147 | 11/147 | 2/71 | 4/72 | 0/33 | 1/31 | 1/65 |
| DyslipidaemiaMetabolism and nutrition disorders | 2/147 | 3/145 | 4/144 | 5/147 | 10/147 | 1/71 | 0/72 | 0/33 | 0/31 | 0/65 |
| DizzinessNervous system disorders | 3/147 | 2/145 | 7/144 | 3/147 | 6/147 | 1/71 | 2/72 | 0/33 | 2/31 | 0/65 |
| NasopharyngitisInfections and infestations | 2/147 | 2/145 | 3/144 | 2/147 | 4/147 | 4/71 | 2/72 | 0/33 | 0/31 | 1/65 |
Treated set (TS): all patients treated with at least 1 dose of study medication
| Age, Continuous(years) | Main: Linagliptin 5mg QD | Main: Metformin 500mg BID | Main: Metformin 1000mg BID | Main: Linagliptin 2.5mg / Metformin 500mg BID | Main: Linagliptin 2.5mg / Metformin 1000mg BID | APG: Linagliptin 5mg QD | APG: Linagliptin 2.5mg / Metformin 1000mg BID | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 50.8 ± 10.5 | 52.1 ± 9.6 | 51.4 ± 10.4 | 51.4 ± 10.2 | 50.7 ± 9.4 | 49.5 ± 11.6 | 49.9 ± 11.7 | 51.0 ± 10.3 |
| Sex: Female, Male(Participants) | Main: Linagliptin 5mg QD | Main: Metformin 500mg BID | Main: Metformin 1000mg BID | Main: Linagliptin 2.5mg / Metformin 500mg BID | Main: Linagliptin 2.5mg / Metformin 1000mg BID | APG: Linagliptin 5mg QD | APG: Linagliptin 2.5mg / Metformin 1000mg BID | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 71 | 54 | 53 | 55 | 60 | 23 | 32 | 348 |
| Male | 76 | 91 | 91 | 92 | 87 | 48 | 40 | 525 |
The record gives a start of Oct 2012, a primary completion of Apr 2014 and a completion of Apr 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2015, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Linagliptin · Metformin